Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Comparison of autologous HCT versus haploidentical donor HCT for Ph+ B-ALL patients following TKI therapy. a study from the global committee and the acute leukemia working party of the european society for blood and marrow transplantation

View Full Paper
Ask AI
Bookmark
Share

Authors

YRYuhua RuDWDepei WuMBMalek Benakli

Discussion

Loading...

Member takes

Overview

Analysis reveals no difference in leukemia-free survival between autologous and haploidentical HCT for Ph+ B-ALL, while relapse incidence varies significantly.

Key Points

  • Haploidentical HCT shows a lower relapse incidence at 10.3% compared to 28% in auto-HCT, suggesting a notable difference in treatment effectiveness.
  • Cytomegalovirus seropositivity rates were higher in haplo-HCT recipients at 67.5%, indicating potential infection risks post-transplant.
  • Minimal residual disease evaluation showed that 81.4% of auto-HCT recipients achieved MRD negativity before transplant, enhancing prognosis.
  • Both transplantation strategies provided similar leukemia-free survival, emphasizing the need for individualized patient approaches and risk assessments.

Cite This Study

Ru et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8b3https://doi.org/10.1182/blood-2025-6080
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparable outcomes of haploidentical, sibling, and unrelated donor transplantation for adult T-ALL in second remission: a study from the global committee and ALWP of the EBMT2025
  2. 2Comparison of outcomes in pediatric patients with acute leukemia undergoing allogeneic HLA-haploidentical hematopoietic stem cell transplantation (HSCT) after in vitro a/b T- and CD19-cell depletion or In Vivo administration of post-transplant cyclophosphamide: An EBMT pediatric working party study2025
  3. 3Autologous stem cell transplantation versus consolidation chemotherapy as post-remission treatment in newly diagnosed favorable and intermediate risk patients with AML: A comparative analysis of HOVON-SAKK-Nordic trials2025
  4. 4Better outcomes with haploidentical than matched sibling donors for adult AML patients allo-transplanted in CR with detectable MRD: A study from the global committee and the ALWP of the EBMT.2025 · 1 citations
  5. 5Hematopoietic cell transplantation after CD19-directed CAR T-cell therapy for remission consolidation or relapse treatment in pediatric acute lymphoblastic leukemia2025